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Abstract 
Background: Malaria in pregnancy is a major cause of adverse maternal and fetal outcomes. Intermittent preventive 
treatment with sulfadoxine–pyrimethamine (IPTp‑SP) is one of the control strategies promoted by WHO. In response 
to mounting resistance to SP, intermittent screening and treatment (ISTp) has been proposed as an alternative. The 
objective of this study was to explore the acceptability of ISTp for health workers and pregnant women.
Methods: Semi‑structured interviews of ten health workers and five focus group discussions of 38 women enrolled 
in an ongoing trial comparing IPTp‑SP and ISTp with dihydroartemisinin–piperaquine (DP) were conducted at two 
antenatal clinics in rural Malawi. All transcripts were coded and themes were identified using a content analysis 
approach.
Results: Amongst health workers, there were contrasting opinions on the preference of blood sampling methods, 
and the influence of method on reliability of diagnosis. The perceived greater effectiveness of DP compared to SP was 
appreciated, however concerns of user compliance with the full dose of DP in non‑trial settings were raised. Despite 
the discomfort of repeated finger pricks, pregnant women were generally accepting of ISTp, particularly the chance 
for regular blood tests to check for infections and the perceived greater effectiveness with fewer side effects of DP 
compared to SP.
Conclusion: In the trial context, pregnant women tended to prefer ISTp‑DP over IPTp‑SP. Health workers were also 
accepting of ISTp‑DP as an alternative to IPTp‑SP in light of increasing SP resistance. However, reliability of stock, 
adherence to malaria test results and user adherence to the full course of DP may present barriers to successful rou‑
tine implementation. Effective communication with health workers and between health workers, pregnant women 
and their communities will be essential for the acceptability of focused antenatal care, including the best malaria 
control measures available.
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Background
Plasmodium falciparum infection in pregnancy has 
been associated with adverse clinical outcomes for both 
the mother and fetus, including severe maternal anae-
mia, low birth weight, pre-term delivery, and perinatal 
mortality [1]. Adverse effects of malaria in pregnancy 
can continue into early childhood, leading to anaemia 
[2–4] and an increased risk of malaria infection in the 
first and second years of life [5–8]. Women who live in 
rural areas, are in their first or second pregnancy [9], are 
infected with human immunodeficiency virus (HIV) [10], 
or are in adolescence, are at greater risk of infection [11, 
12]. Pregnant women in moderate to high transmission 
areas often have asymptomatic infection that frequently 
remains undiagnosed and untreated [13].
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The World Health Organization (WHO) recommends 
a package of interventions to control malaria in preg-
nancy [14], including the early diagnosis and treatment 
of malaria and the use of insecticide-treated nets (ITNs). 
In addition, intermittent preventive treatment (IPTp) 
is also recommended in the sub-Saharan Africa region. 
IPTp involves the administration of an efficacious anti-
malarial drug at each scheduled antenatal care (ANC) 
visit in the second and third trimesters of pregnancy pro-
vided they are no less than a month apart, whether or not 
the woman is parasitaemic [15]. Currently sulfadoxine–
pyrimethamine (SP) is the only anti-malarial used for 
IPTp due to its favourable safety profile [16], cost-effec-
tiveness [17] and single dose regimen. Few anti-malarial 
drugs have a similarly long plasma half-life or can be 
tolerated as well during pregnancy, which has made an 
alternative to SP difficult to find [18]. However, increas-
ing SP resistance is a clear concern for the efficacy and 
effectiveness of IPTp-SP [19, 20].
In the face of increasing SP resistance and lack of evi-
dence on alternative drugs for IPTp, intermittent screen-
ing and treatment in pregnancy (ISTp) offers a possible 
alternative strategy for the control of malaria in preg-
nancy. The concept of ISTp is to provide scheduled 
screening for malaria using a rapid diagnostic test (RDT) 
and to treat RDT-positive women with a long-acting 
artemisinin combination therapy (ACT). The aim is to 
clear existing infections and provide additional post-
treatment prophylaxis for 3–6  weeks. ISTp should be 
delivered at least three times during the second and third 
trimesters of pregnancy as part of focused ANC (fANC) 
[21] and ensures only those women who are parasitaemic 
are exposed to anti-malarial medication [22].
ISTp may be a promising alternative to IPTp-SP for the 
control of malaria in pregnancy [23]. However, its effec-
tiveness under operational conditions depends in part on 
its acceptability to health workers and pregnant women, 
and opportunities for scale-up. The aim of this study was 
to assess the perceptions, experiences and attitudes of 
health workers and pregnant women towards IPTp-SP 
and ISTp using dihydroartemisinin–piperaquine (DP) 
within the context of a randomized controlled superiority 
trial (RCT) conducted in Southern Malawi [22].
Methods
Study site and context within the trial
Malaria is endemic to Malawi with an estimated four mil-
lion episodes of clinical malaria annually [24]. Malaria 
infection during pregnancy remains largely asympto-
matic with evidence of placental malaria in an estimated 
one in four deliveries [25]. According to the Malawi 
Malaria Indicator Survey (MIS) of 2014, 52% of the popu-
lation had access to long-lasting, insecticide-treated nets 
(LLINs), with 70% of households owning at least one net. 
Within the same survey, 62% of pregnant women were 
reported to use a LLIN and 63% reported receiving two 
or more doses of IPTp-SP [24].
This acceptability study was conducted between June 
and July 2012 in Mpemba and Madziabango health cen-
tres in the Southern Region of Malawi, nested within a 
larger clinical trial of the efficacy of ISTp-DP compared to 
IPTp-SP. Methods of the main trial have been described 
elsewhere [22]. Briefly, HIV sero-negative women of all 
gravidae, between 16 and 28 weeks of gestation present-
ing for their first antenatal visit were enrolled and rand-
omized to either the ISTp-SP or ISTp-DP arm. Women 
randomized to the control arm received SP by direct 
observation (DOT) at each antenatal visit, whilst those 
randomized to the ISTp-DP arm were first screened 
with a commercial RDT, and RDT-positive women were 
treated with a standard 3-day course of DP. The dose of 
DP was adjusted for the woman’s weight and all doses of 
DP were supervised. At enrolment, all women had blood 
samples taken by finger prick for HIV and haemoglo-
bin assessment. At each antenatal visit, all women had a 
5 ml venous blood sample drawn for assessment of study 
malaria endpoints and malaria screening in the ISTp arm, 
and routine care including screening for anaemia (at 
the last antenatal visit). RDT results were used to deter-
mine care. Malaria smears and PCR were used to assess 
the trial outcome of plasmodium infection during preg-
nancy; malaria smears were not used for point of care 
and read several weeks after they were taken. Live fetal 
endpoints were collected at delivery to assess babies born 
with a small weight for gestational age, low birth weight 
(<2500  g) or preterm (<37  weeks). Postpartum women 
and newborns were followed-up at 1 and 6  weeks after 
delivery. A LLIN was provided to each woman upon 
enrolment and all participation costs were met by the 
study.
Both trial staff and facility health workers involved 
in providing antenatal services at participating health 
facilities were interviewed. Only women enrolled in the 
trial who had completed the 6-week postnatal visit were 
recruited for the client focus group discussions (FGDs).
Participant selection and interview procedures
Health worker semi‑structured interviews
Health workers from Mpemba and Madziabango health 
centres involved in the delivery of antenatal services, and 
trial staff involved in the clinical trial were purposively 
selected to take part in the study. Trial research nurses 
were responsible for the majority of the trial duties. 
Health workers who were interviewed conducted ‘health 
talks’ to educate pregnant women about ANC and the 
trial. All eligible health workers (facility or trial staff) 
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available on the days that the field team visited the health 
facility were interviewed.
Six‑week postpartum women FGDs
Women who received either ISTp or IPTp-SP as part of 
the trial and were attending the clinic for their 6-week 
postpartum follow-up visit on the day of data collection 
were purposively selected to take part in the study [26]. 
As the recruitment for the FGDs depended on who was 
attending clinic for their postpartum follow-up on the day 
that the fieldworkers were at the facility, they were het-
erogeneous for trial arm to ensure they included enough 
people for discussion. This meant that some women in 
the same discussion group may have experienced IPTp-
SP, while others may have experienced IST-DP; amongst 
those in the ISTp-DP arm, some women may never have 
had a positive RDT and so would not have received DP.
Data collection
This observational study, embedded within an RCT, 
involved primary collection of qualitative data in the form 
of SSIs and FGDs. SSIs were administered to ANC health 
workers and trial staff and lasted between 45  min and 
1.5 h. Interview topic guides included: health worker per-
ceptions of malaria in pregnancy; experiences of the risk 
and consequences of malaria for pregnant women under 
their care; knowledge, experience and opinions of imple-
menting ISTp as part of the trial; prior experience of con-
ducting blood tests; and, opinions on the ISTp strategy if 
it were to be introduced as policy. SSIs were conducted 
in either English or Chichewa, or both in accordance to 
the preference of the interviewee. SSIs conducted in Eng-
lish were facilitated by DA; those conducted in Chichewa 
were facilitated by one of two trained fieldworkers fluent 
in both Chichewa and English.
FGDs were structured around a discussion topic guide 
to understand the experience and perceptions of women 
with respect to their recent pregnancy during the trial. 
Topics included: expectations of ANC visits; reasons for 
repeat visits; and experience with drugs, blood tests and, 
other services received during ANC visits. A key focus 
was to determine women’s opinions of repeated finger 
pricks and blood tests. Respondents were also asked 
to consider, based on their experiences, the potential 
acceptability of ISTp under operational conditions were it 
to become policy. Each FGD was carried out in Chichewa 
and moderated by two trained local facilitators.
Data management
Each SSI and FGD was digitally recorded with informed 
consent, transcribed into Word and kept securely until 
analysis was completed. Those conducted in Chichewa 
were translated directly into English during transcription 
by the two local fieldworkers. All field notes were coded 
to maintain the confidentiality of participants. Transla-
tion and transcription was verified by a local social scien-
tist for quality assurance.
Data analysis
All transcripts were coded and themes were identified 
using a content analysis approach [26]. Information was 
coded using NVivo v9.2 and content analysis was based 
on inductive coding [26]. Themes were identified using a 
combination of a priori issues included in the discussion 
and interview guides that were informed by the research 
question, as well as emergent issues raised by the partici-
pants. Each participant and FGD was assigned a number, 
which is used in the presenting of quotes.
Results
Ten health workers (all female) were interviewed, includ-
ing five research nurses from the research trial team, and 
two nurse midwives, two nurse midwife technicians and 
one community nurse from the health facility staff. Seven 
were located at Mpemba Health Centre, two at Madzi-
abango Health Centre and one divided her time between 
both facilities. Four FGDs of six to nine women each were 
conducted at Mpemba and one FGD of eight women at 
Madziabango. More FGDs were conducted at Mpemba 
due to the greater number of women recruited in the 
ISTp trial at this facility which resulted in a greater num-
ber of women attending the facility for postpartum visits 
during the period of this observational study. A total of 
38 women took part in the FGDs; all were aged between 
16 and 40  years old and most listed their occupation as 
‘housewife’.
Health workers
Five main themes were identified amongst health work-
ers relating to the acceptability of ISTp-SP: blood 
tests, drugs, resources and stock, communication, and 
workload.
Blood tests
Health worker opinions on the acceptability of blood 
tests for ISTp consisted of concerns on the method of 
blood taking, the ability of the test to detect malaria, and 
rumours within the communities regarding blood taking.
Method of blood taking Differing opinions were offered 
by health workers on their own perceptions and those 
of pregnant women on the alternative methods of blood 
sampling. In general, both trial and facility health workers 
perceived that pregnant women found blood tests uncom-
fortable irrespective of the method of sampling used, but 
did not believe this to be a barrier to repeat visits.
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“Some perceive the finger prick as painful; some per-
ceive that peripheral [venous] is painful. We are told 
different things.” (SSI 6, trial staff)
“It is not a big deal, they feel uncomfortable but after 
the whole process is done they forget everything and 
are able to come again for the next antenatal clinic.” 
(SSI 1, health facility staff)
A small number of health workers amongst both trial 
and facility staff felt that venous blood samples were more 
convenient owing to the multiplicity of tests that could be 
conducted on a larger blood sample derived from a single 
blood draw. However, the majority of interviewed health 
workers had a preference for finger prick tests for RDTs 
compared to venous samples due to finger pricks being 
simple and faster to administer. Another reported advan-
tage was that smaller amounts of blood are needed for 
RDTs, which was more acceptable to pregnant women 
who worry about their blood “finishing”. The facility staff 
felt familiar with finger prick tests as they were also used 
for RDTs to detect HIV and syphilis during routine ANC.
“I think RDTs are simple and it’s easier and even to 
the mother it’s acceptable… because they think the 
blood [taken venously] is too much, they say, ‘I’m 
pregnant and you are taking too much blood from 
me, how can I cope?’ but the RDTs they are more 
small and they don’t complain.” (SSI 10, health facil-
ity staff)
Perception of  RDTs and  the influence of  blood sampling 
procedure on  the reliability of  RDT results One of the 
health facility midwifes interviewed reported that she did 
not trust RDTs because they sometimes gave negative 
results when clinical symptoms suggested malaria.
“Testing with these RDTs, it may give negative test 
results yet clinically you are seeing that this patient 
has the signs typical of malaria. That’s when we say 
that I think these devices are not so effective.” (SSI 7, 
health facility staff)
However, all other health workers interviewed (trial 
and facility staff) felt they could trust RDT results and 
that pregnant women were also confident in the diagno-
sis as they could see the results of the RDT. Some health 
workers expressed doubt over the reliability of micros-
copy due to human error and suggested that RDTs were 
more reliable, especially when health workers had less 
experience.
“They don’t doubt when we are using the RDT pro-
cess because they see the whole process, unlike when 
we are using the microscope process.” (SSI 1, health 
facility staff)
“It is effective because when one is positive it means 
she is indeed positive, unlike the microscope way 
because sometimes it’s difficult for the laboratory 
technician to detect the parasites and the results can 
come out negative when one is positive.” (SS1, health 
facility staff)
“I prefer RDTs because in the microscopy, you need 
experience.” (SSI 9, health facility staff)
Comments made by a small number of health work-
ers/trial staff revealed that the method of blood sampling 
can influence confidence in the reliability of RDT results; 
these health workers felt that venous blood samples 
detected ‘real’ malaria due to drawing directly from the 
vein.
“Since we go straight into the vein to take the blood, I 
think we can determine that this is the real malaria 
in the stream.” (SSI 2, health facility staff)
Community rumours regarding  blood draws Health 
workers reported that they were aware of rumours and 
misconceptions within the community regarding blood 
draws for screening tests in the trial, the most prominent 
belief being that the blood taken would be sold.
“They come to the clinic and you draw blood maybe 
to do a certain test, they feel like you’re selling their 
blood.” (SSI 6, trial staff)
Other beliefs reported were blood being used for rea-
sons other than those explained in the trial and that 
blood would be finished in the mother, leaving inade-
quate blood for the baby. Health workers believed these 
rumours which arose during the trial would remain 
in the event that ISTp were to be introduced into rou-
tine service delivery. However, health workers felt these 
misconceptions were not necessarily a barrier to imple-
menting ISTp, as evidenced by the continued compliance 
of women in attending scheduled antenatal visits dur-
ing the trial where venous blood draws were routinely 
conducted; they believed that these rumours could be 
addressed by simple explanation to the women in a way 
they would understand of the convenience of venous 
blood draws for conducting several blood tests from 
a single sample. They also stressed the importance of 
informing and involving husbands and community lead-
ers who have strong influence on pregnant women’s care 
seeking.
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Drugs
Several opinions regarding drug effectiveness and prefer-
ences were expressed by the health workers regarding the 
decreased effectiveness of SP for prevention of malaria 
due to SP resistance, the relative effectiveness of SP and 
DP, prevention versus treatment and drug side effects.
Low effectiveness of SP to prevent malaria due to SP resist-
ance The majority of health workers felt an alternative 
drug to SP was required as SP was no longer effective in 
preventing pregnant women from malaria infection due 
to SP resistance. They also reported that the vast majority 
of women attending antenatal care services at the facili-
ties no longer believed SP prevented malaria and regularly 
asked to enrol into the ISTp trial to benefit from DP which 
they believed was more effective in treating and prevent-
ing malaria.
“They differentiate between SP and DHA [DP]. Most 
of the women want to be on ISTp because they know 
that it is a new drug that we are testing.” (SSI 5, trial 
staff).
DP compared to SP The overriding opinion of the facility 
health workers and trial staff interviewed was that DP was 
more effective than SP as exemplified by the infrequent 
unscheduled visits made by women who received DP.
“If a woman is on ISTp and is taking DHA [DP], it’s 
rare that the woman might come to the clinic with 
malaria, unlike that on IPTp.” (SSI 8, trial staff)
Health workers expressed approval of weight-based 
dosing of DP as opposed to a set dose for everyone, 
although some felt that outside a trial setting the cor-
rect dose would more likely be taken if only whole tablets 
were given due to time constraints in cutting tablets.
“I know how hospitals work – we have lots of 
patients. If the government decide to go with this, are 
they going to manage giving three and a half tablets 
to someone? Will they have time maybe to give one 
half according to the protocol?” (SSI 3, trial staff).
Prevention versus  treatment There was consensus 
amongst health workers that prevention is better than 
cure. However, with the wide perception of decreased 
efficacy of SP and a feeling that women prefer not to take 
drugs during pregnancy if they are not ill, many placed 
emphasis on the promotion of ITNs rather than IPTp-SP 
for prevention. It was also a common opinion that preven-
tion and treatment should work “hand-in-hand” so that 
if prevention has failed, a woman would receive effective 
treatment.
“If the woman is not given a bednet then this woman 
will be coming frequently to the hospital with 
malaria, so I think to prevent first and we can give 
treatment if prevention is failed” (SSI 10, health 
facility staff)
Drug side effects and adherence to treatment All health 
workers involved in the trial gave a favourable opinion of 
DP over SP owing to fewer side effects seen with DP.
“There are few side effects [of DP], if any, I’ve never 
heard of severe side effects.” (SSI 3, trial staff).
However, acceptance by pregnant women to adhere to 
a 3-day DP course without DOT was a clear concern by 
health workers. In the trial, women were provided with 
transportation reimbursements to enable them to attend 
supervised dose administration at the clinic, which would 
not be possible under routine service delivery. As such, 
health workers feared women would be unable to travel 
to ANC daily to receive DOT due to long distances, lim-
ited transportation and costs.
“These women come from afar, so they just buy drugs 
from the shops without coming to the hospital.” (SSI 
8, trial staff)
Other concerns included the perception that if women 
vomited a dose of the drug at home, they would not be 
able to repeat the dose and that some women would not 
receive permission from their husbands to access treat-
ment. Health workers used what they had heard women 
say about taking SP to form their opinions of how likely it 
is they would take DP.
“They will just say, ‘I will take the medicine at home 
because I am coming from very far so I cannot take 
SP here, I have to take it home after eating food,’ but 
then when they go home they just drop the treatment 
without taking it.” (SSI 8, trial staff)
There was wide agreement amongst trial and facility 
health workers that women in the trial would not have 
completed each course of DP if doses two and three had 
been allowed to be taken at home. However, it was also 
agreed that if ISTp were to become government policy, 
adherence to all doses being taken under supervision at 
the clinic would be high as it would be seen as compulsory.
“If it was a government policy, they will be coming 
[to ANC to take DP].” (SSI 5, trial staff)
Resources and stock
A key health worker concern was the likelihood of a con-
tinuous supply of RDTs and medication were ISTp to be 
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introduced as policy. All of the non-trial health workers 
interviewed reported that their facility had experienced 
stock-outs of RDTs outside of the trial. Some maintained 
that SP is always in stock, while others said government 
hospitals routinely run short of drugs. However, they 
noted that the government has been supportive of the 
study and point to this as evidence of the government’s 
commitment to ISTp.
Although presence of stock is a feasibility issue regard-
ing implementation of ISTp, it also has implications for 
health workers’ acceptance of the intervention, which 
appeared to be conditional on a reliable supply of RDTs, 
medicines and other supplies:
“…If we adopt the ISTp then we are relying on RDT, 
then [if RDTs are out of stock] we are going back to 
IPTp – which is very confusing [for the pregnant 
women] … If we have the continuous supply of RDT 
then ISTp will be a success.” (SSI 9, health facility 
staff)
Communication
Health workers were unanimous in saying there was good 
communication between both nurse and patient and 
between themselves and their colleagues. They felt ANC 
attendance was very good with women only occasionally 
missing their appointments, adding that they felt confi-
dent women would attend scheduled screening visits. 
The need for efficient communication and understanding 
between health workers and between health workers and 
their clients and communities was deemed essential in 
acceptance of ISTp by these groups.
“… The problems are not that big that we cannot 
overcome them. We can explain to those people 
who are involved like the village head committee in 
assisting us in explaining to the patients and people 
in the village because it has to start in the commu-
nity so that when they come here, they should not be 
surprised with what’s happening at the hospital. So 
just involving these people I think everything can go 
on well.” (SSI 7, health facility staff)
Work load
Some health workers expressed concern that ISTp would 
increase their work load as there is “more to be done” 
compared to IPTp.
“I think that there can be challenges in areas where 
workers are few. There can be difficulties with follow 
up of patients… and also just doing malaria tests.” 
(SSI 7, health facility staff)
There were suggestions that ISTp could be made more 
acceptable to health workers as far as additional work-
load was concerned by incorporating the screening com-
ponent into tasks already carried out at ANC with task 
shifting to lower cadre staff such as health surveillance 
assistants.
“It can be done after they do the antenatal clinic at 
the booking; they train the HSAs [Health Surveil-
lance Assistants] doing the RDTs for HIV and syphi-
lis, so it can be done at the same time, with the HIV 
and syphilis test and the Hb, so it can be done.” (SSI 
4, trial staff)
Trial participants
Three main themes were identified amongst pregnant 
women relating to the acceptability of ISTp-SP, relating to 
blood tests, drugs and reasons for repeat visits.
Blood tests
Several sub-themes around blood tests emerged that 
influenced the acceptability of ISTp with DP compared to 
IPTp-SP, including: information dissemination by health 
workers of the importance of blood tests; blood sampling 
methods; the relation of blood sampling methods to reli-
ability of test results; the interpretation of the importance 
of blood tests; and social rumours about blood sampling.
Communication by  health workers regarding  blood 
tests Communication between health providers and 
pregnant women was described as being good overall. 
Some women expressed disappointment that reasons for 
their blood tests were not explained to them by the facil-
ity health workers but this was not a shared opinion by 
the majority of the women. Most women believed blood 
tests to be very beneficial. When told the results, women 
reported to have felt more knowledgeable of their well-
being and that of their unborn babies and empowered to 
ensure their continued health.
“We saw this as a great and good thing to know how 
our body is functioning because we used to walk 
without knowing.” (FGD 1)
Blood collection methods The sentiments expressed by 
most women regarding blood sampling revolved around 
the pain that accompanied the sampling procedure. Opin-
ions were however divided on which method was the 
more painful.
“Finger pricks are painful. It’s much better from the 
vein.” (FGD 5)
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“I think that finger pricks are good because it’s not 
like they take a lot of blood.” (FGD 1)
Despite the pain, the overriding opinion was that any 
pain felt was quickly forgotten.
“You feel pain and you forget it, it’s not like you stop 
coming for antenatal clinic just because of that.” 
(FGD 5)
Many expressed a preference for the venous method as 
the same blood sample could be used for multiple RDTs.
“I like my blood being taken from the arm because 
the blood taken is used to find so many diseases.” 
(FGD 2)
Purpose and  reliability of  screening test results based 
on  blood sampling method There was some confusion 
between the belief that the test could detect malaria and 
the method of taking blood. For some there appeared to 
be an intrinsic link between the method of taking blood 
and the disease being tested.
“Most of the time when they are using the finger 
prick tests it means they want to test the blood for 
HIV.” (FGD 2)
“I prefer peripheral tests to RDTs because when they 
do peripheral tests they test us for a lot of infections 
like syphilis, gonorrhoea, AIDS. They can diagnose 
us, unlike doing finger prick tests, they only test for 
one infection.” (FGD 5)
Sentiments were expressed that venous blood sam-
ples provided more reliable results on malaria than fin-
ger-pick blood samples though there were also contrary 
opinions that the ability for a screening test to diagnose 
infection was not dependent on the method used to col-
lect the blood.
“When they are doing the finger prick test they don’t 
take a lot of blood, as a result sometimes it’s difficult 
for them to detect the parasite that causes malaria, 
unlike when they are taking the blood from the arm.” 
(FGD 2)
“If they use the finger prick test, they would say that I 
don’t have any disease when in actual fact, I have it. 
I don’t trust it.” (FGD 2)
“I think they can take blood from anywhere in the 
body and still test it, it’s the same blood.” (FGD 2)
Health decision making empowerment The act of taking 
a finger prick test was seen as empowering for pregnant 
women to be able to make informed decisions to ensure 
the health of themselves and their unborn babies. The 
benefits of blood tests were deemed to outweigh the dis-
comfort experienced during the sampling procedure.
“We know [after having the test] how we are in our 
body and if we are not okay, we are able to protect 
ourselves before the problems arises.” (FGD 4)
Rumours regarding the purpose of blood samples Partici-
pants reported social rumours regarding blood samples 
as their own opinions, the beliefs of their community or 
as both, and it was often difficult to differentiate between 
these viewpoints. As similarly reported by health work-
ers, some FGD participants thought blood taken during 
the trial was being sold, with community perceptions that 
women enrolled in the trial were selling their blood for the 
value of the incentives provided.
“Some said that they are taking your blood in 
exchange for soap or anything that you are given 
there and yet they are making profits out of your 
blood.” (FGD 4)
Some FGD participants reported community percep-
tions that blood samples were kept or taken for occult 
practices. Another belief mentioned during the FGDs 
was that the failure by a woman to attend ANC visits 
would require repayment of a debt by giving blood.
“Others were saying that if you didn’t go for antena-
tal clinic, they would follow you home so that you 
should repay the debt.” (FGD 4)
However, there were no indications that these rumours 
would be sustained if similar volumes of blood were to 
be drawn as part of a screening policy in routine service 
provision which would not be accompanied by any incen-
tives, or follow up visits at home.
By agreeing to have their blood tested, some FGD 
participants believed they were helping their friends 
who have a “shortage of blood”. Others said blood tests 
would lead to the birth of a small baby. Although such 
rumours emerged spontaneously in each FGD and were 
not prompted by the facilitator, in the discussions that 
followed many women said they did not believe the 
rumours and that they are wrong.
Drugs
The effectiveness and replacement of drugs to treat and 
prevent malaria, perceptions of prevention versus treat-
ment, and opinions between DOT and continued unsu-
pervised medication at home were sub-themes that 
emerged from the FGDs.
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Drug effectiveness and  replacement for  prevention 
and treatment Some women within the FGDs remained 
satisfied with SP, stating it still offered protection from 
malaria infection. However, other FGD participants 
believed SP no longer served its purpose and instead left 
them feeling weak, causing them to visit ANC again.
“Sometimes when you took the Fansidar [SP] it 
wasn’t serving its purpose in the body and you could 
go again to be given another one.” (FGD 1)
DP was commonly considered as “the new SP” and 
received positive views by the women, including that 
it gave women strength, was very effective and made 
malaria disappear. Women said DP tablets were slightly 
bigger and a different shape, but that they had no prob-
lems taking them.
“Because when we were given this drug, we were pro-
tected and we never got sick again. Before I started 
antenatal clinic visits I used to get sick and when I 
came here and was given this new drug, I got some 
strength and I was able to work but I wouldn’t work 
beforehand.” (FGD 1)
None of the women reported having experienced side 
effects with DP. In contrast, there were several reports 
that SP sometimes led to dizziness or nausea. This was 
especially associated with receiving SP as IPTp without a 
confirmed diagnosis of malaria.
“Others when they were given Fansidar [SP], they 
were experiencing nausea, so when they were given 
this new drug they were able to differentiate because 
they did not experience any side effects.” (FGD 4)
“When we used to receive Fansidar [SP] without 
being tested…since you take the drug when not sick, 
you started feeling some odd things in the body.” 
(FGD 1).
Prevention versus treatment SP was strongly associated 
with prevention, providing relief for a short period of time 
rather than treatment, whereas DP was seen exclusively 
as treatment.
“There is a difference between these two drugs; Fan-
sidar [SP] protects one from malaria, but then after 
some time malaria symptoms resurfaces again while 
this new drug [DP] heals or rather cures so it’s good 
to go for the new drug because it cures.” (FGD 2)
DOT versus continued medication at home Only a few 
women in each FGD engaged with the issue of adherence, 
but those who did conceded it was sometimes difficult to 
take the full DP course. When asked about likely adher-
ence to completing the full course of DP at home outside 
a trial setting, it was suggested that there may be laziness 
by some women to comply with required adherence and 
a risk that tablets may be misplaced by children in the 
home.
“They give you the medication, you take it and 
because sometimes us women we may be lazy to 
take the medication, we may not properly take it [at 
home].” (FGD 1)
Opinion was equally divided as to whether it would be 
better to take DP at the ANC or at home due to difficulty 
in daily travel or getting permission from their husbands. 
No opinions were expressed about adherence to SP as 
SP was routinely administered as DOT both in the trial 
and as experienced by the women in previous routine 
healthcare.
Reasons for repeat visits
Expectations and previous experiences at prior antenatal 
visits were major influences amongst pregnant women 
to attend subsequent antenatal care visits. Being well 
received and respectfully handled by health workers, 
informed about the wellbeing of their unborn baby and 
reassured of their own health by being tested for HIV and 
other infections, and receipt of medications and LLINs 
were expectations and experiences cited to have pro-
moted high attendance of subsequent visits.
Discussion
Acceptance of ISTp by both health workers and pregnant 
women revolves around several aspects of the interven-
tion as well as interactions between health workers and 
pregnant women and wider community perceptions. 
The study findings show that the opinions and percep-
tions of health workers and pregnant women involved 
in the ISTp trial were interlinked and overlapped on 
several aspects (Fig.  1). Some of the factors underlying 
acceptance of ISTp-DP as an alternative strategy to IPTp-
SP were specific to the particular elements of ISTp-DP. 
Other acceptability issues link more to feasibility of effec-
tive implementation of the strategy under operational 
conditions and how this could influence motivation to 
attend ANC, and so are affected by broader health system 
constraints.
Repeat visits of women to the ANC during their preg-
nancy is central to the success of ISTp both within the 
trial and if IST were to become a policy. As seen else-
where [27–30], this study found that pregnant women do 
not attend ANC solely for malaria screening; they want 
the progress of their babies’ development to be moni-
tored to increase the chance that the baby will be born 
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healthy and without complications. Furthermore, the 
study findings strongly suggest that the likelihood of 
pregnant women complying with repeat visits is related 
to the quality of services and care that they received. All 
women reported their satisfaction with receiving testing 
for infections which are provided as part of routine ANC 
(HIV, syphilis and gonorrhoea) and those in the ISTp 
arm were happy to attend repeat ANC visits to receive 
testing for malaria. It is important to note however, that 
additional resources were available to women enrolled 
in the trial for transportation and other incentives, such 
as LLINs and soap, which would not be available under 
operational conditions. In the context of the trial, health 
workers reported focusing on the increased availability of 
resources and stock within the study to encourage par-
ticipation and repeat visits. This indicates that resources 
and stock may have been identified by pregnant women 
as an obstacle to having their expectations met and 
underlines the importance of monitoring to ensure it 
does not have a future impact on acceptability of ANC 
services once the trial is finished.
An intervention requiring greater implementation 
input will lead to an increase in work load for service pro-
viders. Although some health workers stated their work 
load was manageable, others did not agree, and expressed 
concern that it would worsen with the implementation of 
ISTp as there was “more to be done”. Reasons for these 
mixed opinions may reflect uneven work distribution 
between the different cadres of staff interviewed, or dif-
fering perceptions of work load. Interestingly, however, 
some health workers predicted that their work load 
might actually decrease if ISTp-DP replaced IPTp-SP due 
to fewer unscheduled visits by women attending with 
recurrent clinical malaria in light of perceived reduced 
prophylactic efficacy of IPTp-SP.
Common sub-themes regarding blood tests were dis-
cussed by health workers and pregnant women. For 
example, all were generally supportive of the need and 
importance of blood tests to test for infections during 
pregnancy, and that although taking blood causes dis-
comfort this is outweighed by the benefits to mother and 
baby. Many pregnant women agreed with the idea of being 
tested for an infection before receiving treatment citing 
the discomfort of side effects of unnecessary drugs. This is 
in line with findings of other studies exploring the accept-
ability of ISTp in Ghana and Kenya [27, 28, 30]. The impor-
tance of clear communication in relation to what the tests 
are for, and their results was emphasized by both pregnant 
women and health workers. For example, women reported 
that being able to see the result of an RDT in front of them 
was a very positive factor in believing the diagnosis. Nev-
ertheless, there were contrasting opinions amongst health 
workers and pregnant women about whether microscopy 
or an RDT was more accurate for diagnosing malaria, and 
likewise with respect to whether results were more accu-
rate for blood taken venously or by finger prick.
Although RDTs were described as simple and accurate 
by most health workers, not all were in agreement over 
RDT accuracy, as supported by evidence from elsewhere 
on non-adherence to negative RDTs in the diagnosis 
and treatment of clinical malaria [31–34]. Evidence on 
RDT use amongst pregnant women is limited [35] but a 
recent multi-site qualitative study of the prevention and 
treatment of malaria in pregnancy suggests that trust in 
RDT results is influenced by the complex relationship 
between biomedical malaria and its overlap with gen-
eral symptoms and signs of pregnancy. Generally, posi-
tive RDTs were seen as confirmation of malaria whereas 
negative RDTs were not trusted as confirmation of lack 
of malaria, as the parasites could be “hiding” and this 
could lead to mistrust of the accuracy of RDTs [29, 36]. 
Comments from pregnant women and health facility staff 
in the study also seem to support this observation. This 
is important given the results of the current trial which 
found that RDTs only detected around 45% of PCR-pos-
itive infections in paucigravidae and 30% in multigravi-
dae; as women were treated according to RDT result, this 
may explain the higher prevalence of malaria infections 
at delivery in the ISTp-DP arm [22]. However, it is impor-
tant to note that the biological impact of such low-level 
parasitaemia during pregnancy is unclear [37, 38] and the 
incidence of clinical malaria was not significantly differ-
ent between the trial arms [22]. Compliance with RDT 
result was not an issue in the trial setting but it is unclear 
whether or not non-compliance would be observed in 
a screening strategy involving asymptomatic pregnant 
women under routine conditions. Compliance with best 
practices for the operation of RDTs, and an appreciation 
of the sensitivity and specificity of RDTs by health work-
ers would need to be emphasized in the context of a 
screening strategy to increase health worker acceptability 
[39] and efficiency of implementation of the strategy.
Fig. 1 The relationship between opinions held by health workers 
and pregnant women of intermittent screening and treatment for 
malaria in pregnancy
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Health staff and pregnant women were generally happy 
with the communication between them. This is in con-
trast to other studies which found that poor commu-
nication or staff rudeness contributed to poor ANC 
attendance [40]. This difference may be a reflection of 
the trial setting where clear communication is crucial 
to address concerns and encourage high enrolment and 
retention. Health worker opinions of blood tests and 
their perceptions of how pregnant women feel about 
blood tests are likely to affect how they communicate 
their purpose and importance which could be a possible 
impeding or facilitating factor within the routine setting 
to the acceptability of ISTp.
According to reports from the health workers and 
women in this study, rumours and misconceptions were 
prevalent within the communities regarding venous 
blood draws for screening purposes. Although the sen-
timents of the rumours did not seem to be shared by 
health workers or trial participants, the adverse conse-
quences of the community rumours could prove to be 
a barrier to women attending antenatal care if IST were 
to be implemented as policy, being integrated with other 
routine screening tests such as HIV, syphilis and anae-
mia. This could potentially be addressed by the use of 
finger prick as opposed to venous blood draws in rou-
tine practice, providing a transparent and accountable 
mechanism regarding use of blood samples. The pres-
ence of more unusual and damaging rumours underlines 
the importance of well-trained local health workers that 
are able to address them appropriately without generat-
ing further fear. The general feeling among health work-
ers was that any misunderstanding can be rectified if it 
is properly explained and that health education should 
be emphasized within the community, as supported by 
a similar study assessing acceptability of ISTp in Ghana 
[41].
The opinions of both groups of respondents on SP and 
DP were also interlinked. A key challenge is separating 
opinions of the components of the ISTp intervention with 
the drug used as the two are inextricably linked. Both 
health workers and pregnant women reported observ-
ing that women in the IPTp-SP arm of the trial were fre-
quently ill and experienced more of the consequences 
of malaria in pregnancy and many attributed this to the 
reduced efficacy of SP. DP was the component of ISTp 
most strongly approved of by health workers in light of 
the perceived inferiority of SP. Both health workers and 
pregnant women also perceived that DP had fewer side 
effects than SP for women enrolled in the trial. This is 
interesting, given that the trial found no significant dif-
ferences in clinical malaria or adverse events between the 
two arms [22]. Sentiments regarding the effectiveness of 
either drug by both health workers and pregnant women 
influenced their opinions of the concept of prevention 
versus cure. This was not thought of great importance by 
either due to the overall feeling that IPTp-SP no longer 
provided sufficient protection; a greater preference was 
placed instead on an approach that would combine pre-
vention and effective treatment instead of differentiating 
between them: prevent first (with more emphasis being 
placed on other preventive measures such as ITNs) and 
then treat if the prevention has not worked and a woman 
is found to be positive for malaria parasites. Interestingly, 
this suggestion of a hybrid approach also arose from the 
ISTp-DP acceptability study in Kenya [28].
The participants of this Malawi acceptability study 
had not had any prior exposure to DP for the treatment 
or prevention of malaria prior to enrolment in the trial 
as it is not registered or available in the public sector 
in Malawi. DP for the treatment of confirmed malaria 
is a 3-day course of multiple tablets taken once daily 
as opposed to a single dose of SP taken for IPTp under 
the supervision of a health worker. This raised concerns 
by health workers about adherence to the full course if 
ISTp-DP were to be introduced under operational con-
ditions. FGD participants in the ISTp arm that had been 
diagnosed with malaria during their pregnancy were 
pleased with the DP they received, but most did not 
engage with the issue of adherence, which was a con-
cern raised more by the health workers interviewed. 
This was possibly due to the trial setup as DP was taken 
under clinical supervision and if the pregnant women 
did not attend ANC for their dose they were contacted 
by a member of the study team who provided transport 
if necessary. A woman’s experience of ANC does not 
begin in the consultation room but with the journey to 
the health facility, which may be a considerable distance. 
Health workers were concerned that women may not 
take all doses of DP if unsupervised, but likewise that 
transport limitations may be a significant barrier to preg-
nant women’s acceptability of ISTp if DOT of all three 
doses at a health facility was the recommendation. Previ-
ous research in non-pregnant populations has indicated 
moderate adherence to artemether–lumefantrine (AL) 
for uncomplicated malaria in rural Malawi [42, 43] but 
good unsupervised self-dosing of AL in Tanzania [44] 
and of artesunate–amodiaquine in Ghana [23]. The evi-
dence base for adherence to treatment of malaria with an 
ACT during pregnancy is smaller and mixed. For exam-
ple, a recent study from the Gambia [45] reported that 
despite high knowledge of the biomedical importance 
of malaria infection by pregnant women, adherence to 
anti-malarial treatment was low, usually discontinuing 
treatment after prescription for several reasons including 
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perceived ineffectiveness of treatment, risk of medica-
tion, family influence, and denial of diagnosis of disease. 
In contrast, a study of the acceptability of ISTp alongside 
a clinical trial in Northern Ghana found that adherence 
to self-administered AL by trial participants (determined 
by inspection of blister packets) was high [30]. Helpful 
packaging, pictorial dosing instructions and patient con-
viction that the strategy is effective can all contribute to 
increased adherence [44] although barriers to compli-
ance with self-continued treatment of ISTp-DP by preg-
nant women at home would require careful attention.
Limitations
Although the findings of the study favour the acceptabil-
ity of ISTp-DP as an alternative to IPTp-SP, it is impor-
tant to recognize that the experiences and opinions of the 
two strategies expressed by pregnant women and health 
providers in this study were within the context of a clini-
cal trial. The additional resources that this brings, includ-
ing uninterrupted supplies of RDTs and anti-malarials, 
trial staff dedicated to the delivery of the interventions, 
direct observation of all doses of DP and reimburse-
ment of travel expenses for participants, are unlikely to 
be replicated if ISTp-DP were to be implemented under 
routine care. Similarly, the strong levels of communica-
tion between health workers, trial staff and participants 
may have influenced the attitudes and perceptions of the 
pregnant women with respect to the efficacy and accept-
ability of IPTp-SP and IST-DP. The perceived superiority 
of DP compared to SP for example is in contrast to the 
trial results which found no significant difference in clini-
cal malaria between the two arms and may be a result of 
respondents believing that the new drug must be better 
than the existing one it was being tested against; due to 
the nature of the interventions, study participants and 
health staff could not be blinded to the arm of allocation.
In addition, recruitment of pregnant women to the 
FGDs depended on who was attending the clinic for 
their postpartum follow up visit on the day that the study 
team was present. As such, it was not possible to design 
the composition of the FGDs with respect to trial arm 
and experience of the different interventions as has been 
done in previous studies [27, 28]. This means that the 
women involved in the qualitative study may not be fully 
representative of the trial population as a whole. How-
ever, women of different age, parity and trial arm were 
included and a range of opinion was elicited. Neverthe-
less, it is possible that the small number of FGDs means 
that saturation of opinions may not have been reached.
It would be of interest to conduct a feasibility study in 
this setting to explore the relative importance of these 
factors that would influence effective implementation of 
ISTp-DP if it were to become policy.
Conclusion
This is the first study to explore health worker and preg-
nant women acceptability of ISTp within a trial con-
text in Malawi and to explore the possible implications 
for acceptability were ISTp to become national policy. 
In order for ISTp with DP to be an acceptable strategy, 
pregnant women must understand the consequences of 
any malaria infection during pregnancy, the importance 
of scheduled screening for malaria and, if diagnosed 
with malaria, adherence to treatment in an unsuper-
vised setting. This understanding must be guided by a 
clear message from health workers to avoid the emer-
gence of rumours and misconception. Although IPTp 
was acknowledged by some health workers to have 
advantages over ISTp, such as simplicity and compliance, 
almost all focused on its drawbacks particularly a per-
ceived decrease in effectiveness with increasing SP resist-
ance. Overall, they approved of ISTp and wanted it to 
become a permanent policy in place of IPTp. There was 
strong agreement that pregnant women would accept 
and adhere to ISTp if it were to become government 
health policy as it is viewed as compulsory; this is sup-
ported by pregnant women’s trust in services provided 
during their antenatal care which will improve the health 
of their babies. The interviews and FGDs analysed in this 
paper were conducted before the results of the trial were 
published and IST-DP was found to be non-superior to 
IPTp-SP in this setting. However, the factors influencing 
acceptability of ISTp cannot be separated from factors 
influencing acceptability of focused ANC, for example an 
appreciation by pregnant women of regular blood tests 
and strong communication about the progress of their 
pregnancy. Adherence to scheduled ANC visits along 
with the best malaria control measures available should 
be further encouraged with emphasis placed on com-
munity-based strategies to strengthen ties between the 
formal health sector and local communities. However, 
feasibility factors that would influence quality of services 
provided such as a reliable supply of commodities must 
also be considered in determining the potential success 
of any strategy for the control of malaria in pregnancy.
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